Testing a new drug for cancers with KRAS G12D mutation
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced, cannot be removed by surgery, and measurable on scans.
- You must have a specific change in your tumor's DNA called KRAS G12D.
- You must be in relatively good health (able to get out of bed and do light activities).
- You must have already tried at least one standard chemotherapy for your cancer.
- If you have had brain metastases, they must be treated and stable, with no current symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests an experimental drug (GDC-7035) given with other cancer treatments to see if it is safe and works in people with advanced colorectal or pancreatic cancer that has a specific genetic change called KRAS G12D.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.